Addition of King Pharmaceuticals’ Alpharma business broadens Pfizer Animal Health’s best-in-class portfolio
MADISON, N.J., March 2, 2011 - With the acquisition of King Pharmaceuticals by Pfizer, Inc. announced on February 28, Pfizer Animal Health will begin integrating Alpharma, LLC into its existing business, providing customers with a more diversified portfolio of products and services. Pfizer Animal Health is the leader in the discovery, manufacturing and marketing of veterinary vaccines and medicines within the U.S. animal health market, and will become a leading marketer in the U.S. medicated feed additives business. Alpharma was a wholly owned subsidiary of King Pharmaceuticals and became part of Pfizer Animal Health with Pfizer’s acquisition of King.
The integration of Alpharma allows Pfizer Animal Health to build on its already broad product portfolio of biologics, medicines and immunodiagnostics with Alpharma’s industry-leading array of medicated feed additives and water-soluble therapeutics for the prevention and treatment of diseases.
“Pfizer Animal Health welcomes Alpharma colleagues and the company’s respected products and services,” said Clint Lewis, President of U.S. Operations for Pfizer Animal Health. “Today marks another important milestone in Pfizer Animal Health’s evolution in offering veterinarians, nutritionists and all our customers a more comprehensive portfolio of unique products and services. It also further demonstrates our commitment to becoming a complete solutions provider for our customers.”
Broader Solutions for Customers
The U.S. animal health industry has come to rely and depend on the availability, effectiveness and safety of Pfizer Animal Health’s products. Already an industry leader, Pfizer now adds Alpharma brands such as BOVATEC® (lasalocid), AUREOMYCIN® (chlortectracycline), DECCOX® (decoquinate) and BMD® (bacitracin methylene disalicylate) to its offerings. These products complement the Pfizer portfolio that includes DRAXXIN® (tulathromycin), EXCEDE® (ceftiofur crystalline free acid), Bovi-Shield ® GOLD, FACTREL® (gonadorelin hydrochloride), the line of SYNOVEX® implants, as well as RESPISURE®, FLUSURE®, and the full line of SUVAXYN® brands.
“The Alpharma integration, coupled with our recent acquisition of Synbiotics Corporation, showcases Pfizer Animal Health’s continued desire to find ways to expand our portfolio to best meet customer needs within a changing marketplace,” Lewis said. “We want to be viewed by customers and colleagues as the best animal health company with exceptional people, products and services.”
Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com .
The information contained in this release is as of March 1, 2011. Pfizer assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information that involves substantial risks and uncertainties about Pfizer’s acquisition of King Pharmaceuticals, Inc., including its potential benefits, and the anticipated cost savings and impact on adjusted diluted
earnings per share of the transaction. Such risks and uncertainties include, among other things, the potential effects of disruption from the transaction; other business effects, including the effects of industry, economic, political or regulatory conditions outside of
Pfizer's and King’s control; transaction costs; actual or contingent liabilities; Pfizer's ability to realize the projected synergies from its acquisition of King; and other uncertainties related to the business of King and Pfizer.
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report of Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K.